Ardena divests Södertälje drug substance site to Nanologica – European Pharmaceutical Review

About us | Advertise with us | Contact us


Posted: 3 February 2026 | Dominic Tyer (European Pharmaceutical Review) | No comments yet
The CDMO and CRO’s Swedish API facility will now operate as a Nanologica subsidiary, reverting to its original name Syntagon.
Belgium firm Ardena has divested its active pharmaceutical ingredient (API) site in Södertälje to Swedish life science tools company Nanologica.
FREE WEBINAR : Practical Considerations for Aseptic Gowning in Contamination Control Strategies
Join this webinar as we examine the main personnel-related factors that could lead to particle/microbial contamination risks of the product and outline practical measures that can mitigate these risks.
REGISTER NOW!
The deal will see contract development and manufacturing organisation (CDMO) and bioanalytical contract research organisation (CRO) Ardena take a stake in Nanologica and its CEO Jeremie Trochu will join Nanologica’s Board of Directors.
Trochu said: “This transaction supports Ardena’s strategy to focus investment and growth on specialised capabilities that enable precision medicines and deliver meaningful patient impact across drug product, nanomedicine, drug conjugates, biomarkers and bioanalysis.
“Nanologica is a partner we know well and is ideally positioned to build on the strong foundation in Södertälje and offer an exciting future for the site.”
The facility is an established API CDMO with more than 45 employees that supports programmes across early development, clinical supply and commercial manufacturing.
The Södertälje business will now operate as a wholly owned subsidiary within the Nanologica Group and will revert to its original name Syntagon.
Meanwhile, Ardena last month won a contract from New York-based, cancer focused biotech Nouveau Biosciences to manufacturing its lead asset Kromastat (previously known as NBS-M001). Nouveau Biosciences will work with Ardena, which has a nanomedicine facility in the Netherlands, to progress its proprietary drug discovery technology that uses polymer-based nanochemistry to enhances drug targeting, tolerability and efficacy.
Active Pharmaceutical Ingredient (API), Contract Development and Manufacturing Organisation (CDMO), Contract Manufacturing, Contract Research Organisations (CROs), Nano-medicine
Ardena, Nanologica, Nouveau Biosciences, Syntagon
Kromastat
Jeremie Trochu
By Dominic Tyer (European Pharmaceutical Review)
3 February 2026
No comments yet
Active Pharmaceutical Ingredient (API), Contract Development and Manufacturing Organisation (CDMO), Contract Manufacturing, Contract Research Organisations (CROs), Nano-medicine
Ardena, Nanologica, Nouveau Biosciences, Syntagon
Kromastat
Jeremie Trochu
All subscriptions include online membership, giving you access to the journal and exclusive content.
By Dominic Tyer (European Pharmaceutical Review)
By Dominic Tyer (European Pharmaceutical Review)
By Dominic Tyer (European Pharmaceutical Review)
By Dominic Tyer (European Pharmaceutical Review)
Your email address will not be published. Required fields are marked *
Comment *
Name *
Email *
Website

Write for us | Advertise with us
T: +44 (0)1959 563311
F: +44 (0)1959 563123

European Pharmaceutical Review is published by:
Russell Publishing Ltd.
Court Lodge
Hogtrough Hill
Brasted, Kent, TN16 1NU
United Kingdom
© Russell Publishing Limited, 2010-2026. All rights reserved.
Website development by e-Motive Media Limited.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

source